Per citar aquest document: http://ddd.uab.cat/record/132804
BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS
Peluffo, Hugo (Universidad de la República (Uruguay). Departamento de Histología y Embriología)
Unzueta Elorza, Ugutz (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Negro-Demontel, María Luciana (Universidad de la República (Uruguay). Departamento de Histología y Embriología)
Xu, Zhikun (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Ferrer Miralles, Neus (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)

Data: 2015
Resum: The increasing incidence of diseases affecting the central nervous system (CNS) demands the urgent development of efficient drugs. While many of these medicines are already available, the Blood Brain Barrier and to a lesser extent, the Blood Spinal Cord Barrier pose physical and biological limitations to their diffusion to reach target tissues. Therefore, efforts are needed not only to address drug development but specially to design suitable vehicles for delivery into the CNS through systemic administration. In the context of the functional and structural versatility of proteins, recent advances in their biological fabrication and a better comprehension of the physiology of the CNS offer a plethora of opportunities for the construction and tailoring of plain nanoconjugates and of more complex nanosized vehicles able to cross these barriers. We revise here how the engineering of functional proteins offers drug delivery tools for specific CNS diseases and more transversally, how proteins can be engineered into smart nanoparticles or ‘artificial viruses’ to afford therapeutic requirements through alternative administration routes.
Nota: The authors acknowledge the financial support granted to H.P. and L.N. from Fundació Marató TV3, Catalunya, Spain (TV32011-110533), Comisión Sectorial de Investigación Científica de la Universidad de la República (CSIC-UDELAR), Uruguay, Agencia Nacional de Investigación e Innovación (ANII), Uruguay, and FOCEM (MERCOSUR Structural Convergence Fund), COF 03/11, to E.V. from FIS (PI12/00327) and Fundació Marató TV3 (TV32013-133930) and to A.V. from Fundació Marató TV3 (TV32013-132031), MINECO (BIO2013-41019-P) and from the Centro de Investigación Biomédica en Red (CIBER) de Bioingeniería, Biomateriales y Nanomedicina, with assistance from the European Regional Development Fund, for their nanomedical research. Z.X. and U.U. acknowledge financial support from China Scholarship Council(2011630065) and from ISCIII(FI09/00150) respectively, both through pre-doctoral fellowships. A.V. has been distinguished with an ICREA ACADEMIA award.
Nota: Número d'acord de subvenció MINECO/BIO2013-41019P
Nota: Número d'acord de subvenció ISCIII/FIS/PI12/00327
Drets: Tots els drets reservats.
Llengua: Anglès.
Document: article ; recerca ; acceptedVersion
Matèria: Nanoparticles ; Nanopartícules ; BBB ; Protein engineering ; Enginyeria de proteïnes ; Recombinant proteins ; Proteïnes recombinants ; Artificial viruses ; Virus artificials ; Drug delivery ; Administració de medicaments ; Gene therapy ; Teràpia genètica
Publicat a: Biotechnological advances, Vol. 33, Issue 2 (March-April 2015) , p. 277-287

DOI: 10.1016/j.biotechadv.2015.02.004


Post-print
40 p, 590.7 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2015-06-18, darrera modificació el 2016-06-09



   Favorit i Compartir